To prospectively assess treatment response using volumetric functional magnetic resonance imaging ( MRI ) metrics in patients with hepatocellular carcinoma ( HCC ) treated with the combination of doxorubicin-eluting bead-transarterial chemoembolization ( DEB TACE ) and sorafenib .